An interventional study of PROGEN in ACL Reconstruction, sponsored by OPKO Health, Inc.. Completed. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2017-11-30.
Sponsored by OPKO Health, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This was a prospective, multicenter, randomized, open-label, phase IV trial to compare the efficacy of supplementation with plasma proteins, hydrolyzed collagen (CH), a complex of HA-CS (HC-15), and vitamin C combined with a standard rehabilitation protocol versus the standard rehabilitation protocol only after arthroscopically-assisted functional ACL reconstruction with hamstrings.
626 studies on the registry are indexed under Anterior Cruciate Ligament Injuries; 193 are open to participants now.
This study's enrollment of 80 is above the median of 56 across 459 interventional studies indexed under Anterior Cruciate Ligament Injuries.
Browse Anterior Cruciate Ligament Injuries studies →OPKO Health, Inc. is the lead sponsor of 49 studies on the registry; 2 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 7 (78%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PROGEN + Standard Rehabilitation + ACL reconstruction
Dietary Supplement: PROGEN
Standard Rehabilitation + ACL reconstruction
Dietary supplement based on plasma proteins, hydrolyzed collagen, a complex of Hyaluronic Acid - Chondroitin Sulfate (HC-15), and vitamin C
Pain improvement
Assessed using a 100-mm Visual Analog Scale (VAS)
Time frame: 90 days
Knee function
Assessed using the International Knee Documentation Committee (IKDC) index. The final score was interpreted as a measure of function, with higher scores representing higher levels of function
Time frame: 90 days
Analgesic consumption
Analgesic consumption and frequency of analgesic intake during follow-up
Time frame: 90 days
Number of rehabilitation sessions required
Number of required rehabilitation sessions at the end of follow-up.
Time frame: 90 days
Maduration of the graft
Assessed by MRI, by a single blind muskuloskeletal radiologist, using a standard procedure based on ACL oblique parasagittal T1 sequences
Time frame: Day 0, day 90
Perceived efficacy and tolerability by both patients and physicians
Perceived efficacy and tolerability were rated by both patients and physicians on a 5-point Likert scale, where higher scores indicated better efficacy and tolerability
Time frame: 90 days
Safety
Assessed by means of all adverse events (AE) treatment related, reported at the end of follow-up.
Time frame: 90 days
No study locations are listed for this record.
Plan to share: No
Ran from Mar 2015 to primary completion in Feb 2017, 22 months.
Of 287 interventional studies with no phase under Anterior Cruciate Ligament Injuries, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 70. This study's 22 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Conjugated estrogens
Anterior Cruciate Ligament Injuries →